28th Mar 2018 10:41
Takeda made the announcement after press reports of interest in the Irish drugmaker sent its shares 24% higher to
"Takeda confirms that it is considering making an approach to Shire regarding a possible offer for the company," Takeda said in a statement. "Takeda's consideration of such an offer is at a preliminary and exploratory stage and no approach has been made to the board of Shire. There can be no certainty that an approach, if made, will lead to any transaction".
Takeda emphasised it "continuously considers" options with regards to accelerating its growth. In particular, it is focused on growing its core gastroenterology, oncology and neuroscience plus vaccines.
The deal with Shire - should it emerge - would "strengthen" its core therapeutic areas.
"Clearly defined strategic and financial objectives are core to Takeda's disciplined approach to acquisitions," Takeda cautioned, "including in relation to its dividend policy and credit rating, which are well-established. Any potential offer for Shire, if made, would have to align with this strict investment criteria".
Related Shares:
Shire